Intensity Therapeutics Common Stock Performance
| INTS Stock | 0.22 0.03 12.00% |
The company retains a Market Volatility (i.e., Beta) of 2.38, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Intensity Therapeutics will likely underperform. At this point, Intensity Therapeutics has a negative expected return of -0.65%. Please make sure to check out Intensity Therapeutics' treynor ratio and daily balance of power , to decide if Intensity Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Intensity Therapeutics Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor 1:25 | Last Split Date 2026-02-19 |
1 | Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium | 12/04/2025 |
2 | Intensity Therapeutics receives 180-day Nasdaq extension to regain compliance | 12/05/2025 |
3 | Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium | 12/11/2025 |
4 | Acquisition by Talamo Joseph of 14482 shares of Intensity Therapeutics at 0.262 subject to Rule 16b-3 | 12/31/2025 |
5 | Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities | 01/13/2026 |
6 | Acquisition by Wesolowski John M of 8918 shares of Intensity Therapeutics at 0.262 subject to Rule 16b-3 | 01/15/2026 |
7 | Acquisition by Donovan Daniel of 50000 shares of Intensity Therapeutics at 0.57 subject to Rule 16b-3 | 01/27/2026 |
8 | Acquisition by Bender Lewis H of 33574 shares of Intensity Therapeutics at 5.19 subject to Rule 16b-3 | 02/13/2026 |
| Begin Period Cash Flow | 8.6 M | |
| Total Cashflows From Investing Activities | 6.4 M | |
| Free Cash Flow | -15.2 M |
Intensity | Build AI portfolio with Intensity Stock |
Intensity Therapeutics Relative Risk vs. Return Landscape
If you would invest 38.00 in Intensity Therapeutics Common on November 20, 2025 and sell it today you would lose (16.00) from holding Intensity Therapeutics Common or give up 42.11% of portfolio value over 90 days. Intensity Therapeutics Common is currently does not generate positive expected returns and assumes 7.0698% risk (volatility on return distribution) over the 90 days horizon. In different words, 63% of stocks are less volatile than Intensity, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Intensity Therapeutics Target Price Odds to finish over Current Price
The tendency of Intensity Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.22 | 90 days | 0.22 | close to 99 |
Based on a normal probability distribution, the odds of Intensity Therapeutics to move above the current price in 90 days from now is close to 99 (This Intensity Therapeutics Common probability density function shows the probability of Intensity Stock to fall within a particular range of prices over 90 days) .
Intensity Therapeutics Price Density |
| Price |
Predictive Modules for Intensity Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Intensity Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Intensity Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intensity Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Intensity Therapeutics is not an exception. The market had few large corrections towards the Intensity Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Intensity Therapeutics Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Intensity Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.65 | |
β | Beta against Dow Jones | 2.38 | |
σ | Overall volatility | 0.06 | |
Ir | Information ratio | -0.07 |
Intensity Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Intensity Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Intensity Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Intensity Therapeutics generated a negative expected return over the last 90 days | |
| Intensity Therapeutics has high historical volatility and very poor performance | |
| Intensity Therapeutics has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (16.27 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Intensity Therapeutics generates negative cash flow from operations | |
| Intensity Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Donovan Daniel of 50000 shares of Intensity Therapeutics at 0.57 subject to Rule 16b-3 |
Intensity Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Intensity Stock often depends not only on the future outlook of the current and potential Intensity Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Intensity Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 13.9 M | |
| Cash And Short Term Investments | 2.6 M |
Intensity Therapeutics Fundamentals Growth
Intensity Stock prices reflect investors' perceptions of the future prospects and financial health of Intensity Therapeutics, and Intensity Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Intensity Stock performance.
| Return On Equity | -2.35 | ||||
| Return On Asset | -1.02 | ||||
| Current Valuation | 8.08 M | ||||
| Shares Outstanding | 60.06 M | ||||
| Price To Book | 2.08 X | ||||
| EBITDA | (16.27 M) | ||||
| Net Income | (16.27 M) | ||||
| Total Debt | 138 K | ||||
| Book Value Per Share | 0.15 X | ||||
| Cash Flow From Operations | (15.22 M) | ||||
| Earnings Per Share | (0.55) X | ||||
| Market Capitalization | 13.42 M | ||||
| Total Asset | 4.78 M | ||||
| Retained Earnings | (66.78 M) | ||||
| Working Capital | 1.61 M | ||||
About Intensity Therapeutics Performance
Assessing Intensity Therapeutics' fundamental ratios provides investors with valuable insights into Intensity Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Intensity Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.91) | (4.11) | |
| Return On Capital Employed | (6.30) | (5.98) | |
| Return On Assets | (3.91) | (4.11) | |
| Return On Equity | (6.41) | (6.09) |
Things to note about Intensity Therapeutics performance evaluation
Checking the ongoing alerts about Intensity Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Intensity Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Intensity Therapeutics generated a negative expected return over the last 90 days | |
| Intensity Therapeutics has high historical volatility and very poor performance | |
| Intensity Therapeutics has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (16.27 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Intensity Therapeutics generates negative cash flow from operations | |
| Intensity Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Donovan Daniel of 50000 shares of Intensity Therapeutics at 0.57 subject to Rule 16b-3 |
- Analyzing Intensity Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Intensity Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Intensity Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Intensity Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Intensity Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Intensity Therapeutics' stock. These opinions can provide insight into Intensity Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Intensity Stock Analysis
When running Intensity Therapeutics' price analysis, check to measure Intensity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intensity Therapeutics is operating at the current time. Most of Intensity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intensity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intensity Therapeutics' price. Additionally, you may evaluate how the addition of Intensity Therapeutics to your portfolios can decrease your overall portfolio volatility.